Advertisement

Drugs

, Volume 78, Issue 17, pp 1835–1839 | Cite as

Vibegron: First Global Approval

  • Susan J. KeamEmail author
AdisInsight Report

Abstract

Vibegron is a selective beta 3 adrenergic receptor (β3AR) agonist that is being developed in Japan jointly by Kyorin Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd and in other regions worldwide (except in several other Asian countries) by Urovant Sciences for the treatment of overactive bladder (OAB). Based on results from Japanese phase III trials, vibegron received approval in Japan in September 2018 for this indication. This article summarizes the milestones in the development of vibegron leading to this first global approval for the treatment of OAB.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan Keam is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Kyorin Pharmaceutical. Beova Tablets 50 mg: Japanese prescribing information. 2018. http://www.info.pmda.go.jp/downfiles/ph/PDF/230109_25900A7F1025_1_02.pdf. Accessed 3 Oct 2018.
  2. 2.
    Kyorin Pharmaceutical. Kyorin and Kissei signed an agreement for co-development and co-marketing of KRP-114V [media release]. 30 Mar 2016.Google Scholar
  3. 3.
    Roivant Sciences. Roivant Sciences launches Urovant to develop innovative therapies in urology [media release]. 6 Jun 2017.Google Scholar
  4. 4.
    Di Salvo J, Nagabukuro H, Wickham LA, et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther. 2017;360(2):346–55.CrossRefGoogle Scholar
  5. 5.
    Urovant Sciences. Pipeline. 2018. https://urovant.com/pipeline/. Accessed 24 Oct 2018.
  6. 6.
    Kyorin Pharmaceutical. Kyorin signed a license agreement with Merck on vibegron for overactive bladder in Japan [media release]. 22 Jul 2014.Google Scholar
  7. 7.
    Kyorin Holdings Inc. Kyorin acquired licenses from Merck & Co., Inc., Kenilworth, N.J., U.S.A. for investigational therapy for overactive bladder (Code:KRP-114V) in Asia [media release]. 11 Apr 2017.Google Scholar
  8. 8.
    Urovant Sciences Ltd SEC filing. 2018. https://www.nasdaq.com/markets/ipos/filing.ashx?filingid=12859913. Accessed 9 Oct 2018.
  9. 9.
    Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609–23.CrossRefGoogle Scholar
  10. 10.
    Yoshida M, Kakizaki H, Takahashi S, et al. Long-term safety and efficacy of the novel beta3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study. Int J Urol. 2018;25(7):668–75.CrossRefGoogle Scholar
  11. 11.
    Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–90.CrossRefGoogle Scholar
  12. 12.
    Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2018.  https://doi.org/10.1016/j.eururo.2018.10.006.CrossRefPubMedGoogle Scholar
  13. 13.
    Dmochowski R, Mitcheson D, Frenkl T, et al. Durable efficacy and safety of long-term once-daily vibegron, a novel oral B-3 adrenergic receptor agonist: a 52-week phase 2 study in patients with overactive bladder syndrome [abstract no. PD50-03]. J Urol. 2018;199(4 Suppl):e970-e1.Google Scholar
  14. 14.
    Kyorin Pharmaceutical. Kyorin receives marketing approval in Japan for “Beova® tablets 50 mg” for the treatment of overactive bladder [media release]. 21 Sep 2018.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations